Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer
We conducted a prospective Phase II study to determine the response rate, toxicity, and 2-year survival rate of concurrent weekly paclitaxel and radiation therapy (RT) for locally advanced unresectable non-small cell lung cancer. The weekly paclitaxel regimen was designed to optimize the radiosensit...
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 1998-08, Vol.4 (8), p.1931-1936 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1936 |
|---|---|
| container_issue | 8 |
| container_start_page | 1931 |
| container_title | Clinical cancer research |
| container_volume | 4 |
| creator | CHOY, H SAFRAN, H AKERLEY, W GRAZIANO, S. L BOGART, J. A COLE, B. F |
| description | We conducted a prospective Phase II study to determine the response rate, toxicity, and 2-year survival rate of concurrent
weekly paclitaxel and radiation therapy (RT) for locally advanced unresectable non-small cell lung cancer. The weekly paclitaxel
regimen was designed to optimize the radiosensitizing properties of paclitaxel. Thirty-three patients with unresectable stage
IIIA and IIIB non-small cell lung cancer from six institutions were entered into the study between March 1994 and February
1995. Weekly i.v. paclitaxel (60 mg/m2; 3-h infusion) plus concurrent chest RT (60 Gy over 6 weeks) was delivered for 6 weeks.
Twenty-nine patients were evaluable for response. Three patients achieved a complete response (10%), and 22 patients (76%)
achieved a partial response, for an overall response rate of 86% (95% confidence interval, 68-96%). One patient progressed
during the therapy, and three patients had stable disease. Esophagitis was the principal toxicity. Grade 3 or 4 esophagitis
occurred in 11 patients (37%). One patient died of pneumonia after completion of therapy. Additional grade > or =3 toxicities
included pneumonitis (12%) and neutropenia (6%). One patient had a grade 3 hypersensitivity reaction. The median overall survival
duration for all 33 patients who entered the study was 20 months, and 1-, 2-, and 3-year overall survival rates were 60.6%,
33.3%, and 18.2%, respectively. The median progression-free survival duration for all 33 patients was 10.7 months, and 1-,
2-, and 3-year progression-free survival rates were 39.4%, 12.1%, and 6.1%, respectively. Weekly paclitaxel plus concurrent
RT is a well-tolerated outpatient regimen. The survival outcome from this regimen is encouraging and seems to be at least
equivalent to that of other chemotherapy/radiation trials. These findings warrant further clinical evaluation of weekly paclitaxel/RT
in Phase II trials in the neoadjuvant setting and in combination with other cytotoxic agents. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_9717821</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9717821</sourcerecordid><originalsourceid>FETCH-LOGICAL-h267t-6a450ad39b52111fec510facceefaffbd9713f70dc9d9e09660168e73288e49e3</originalsourceid><addsrcrecordid>eNo9j01LAzEQhhdRaq3-BCEHwdNCstmvHKX4USjoQc_LNJl0o2l2SbLW_nsjLV5mhnmfGd73LJuzqmpyXtTVeZpp0-a05MVldhXCJ6WsZLScZTPRsKYt2DyLbz0EJKsVid6AJYMme8QveyAjSGsi_KAl4BSRg5OT9-gi8aAMRDM4Env0MB6IHjyxgwSb7kB9g5OoiBtcHnZpRySmYie3JfJP8tfZhQYb8ObUF9nH0-P78iVfvz6vlg_rvC_qJuY1lBUFxcWmKhhjGmXFqAYpETVovVEpBdcNVVIogVTUNWV1iw0v2hZLgXyR3R7_jtNmh6obvdmBP3Sn9Em_O-kQknntkzsT_rGC15XgZcLuj1hvtv3eeOyOMTwGBC_7ruzajgnO-C8NRnPA</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>American Association for Cancer Research</source><source>Alma/SFX Local Collection</source><creator>CHOY, H ; SAFRAN, H ; AKERLEY, W ; GRAZIANO, S. L ; BOGART, J. A ; COLE, B. F</creator><creatorcontrib>CHOY, H ; SAFRAN, H ; AKERLEY, W ; GRAZIANO, S. L ; BOGART, J. A ; COLE, B. F</creatorcontrib><description>We conducted a prospective Phase II study to determine the response rate, toxicity, and 2-year survival rate of concurrent
weekly paclitaxel and radiation therapy (RT) for locally advanced unresectable non-small cell lung cancer. The weekly paclitaxel
regimen was designed to optimize the radiosensitizing properties of paclitaxel. Thirty-three patients with unresectable stage
IIIA and IIIB non-small cell lung cancer from six institutions were entered into the study between March 1994 and February
1995. Weekly i.v. paclitaxel (60 mg/m2; 3-h infusion) plus concurrent chest RT (60 Gy over 6 weeks) was delivered for 6 weeks.
Twenty-nine patients were evaluable for response. Three patients achieved a complete response (10%), and 22 patients (76%)
achieved a partial response, for an overall response rate of 86% (95% confidence interval, 68-96%). One patient progressed
during the therapy, and three patients had stable disease. Esophagitis was the principal toxicity. Grade 3 or 4 esophagitis
occurred in 11 patients (37%). One patient died of pneumonia after completion of therapy. Additional grade > or =3 toxicities
included pneumonitis (12%) and neutropenia (6%). One patient had a grade 3 hypersensitivity reaction. The median overall survival
duration for all 33 patients who entered the study was 20 months, and 1-, 2-, and 3-year overall survival rates were 60.6%,
33.3%, and 18.2%, respectively. The median progression-free survival duration for all 33 patients was 10.7 months, and 1-,
2-, and 3-year progression-free survival rates were 39.4%, 12.1%, and 6.1%, respectively. Weekly paclitaxel plus concurrent
RT is a well-tolerated outpatient regimen. The survival outcome from this regimen is encouraging and seems to be at least
equivalent to that of other chemotherapy/radiation trials. These findings warrant further clinical evaluation of weekly paclitaxel/RT
in Phase II trials in the neoadjuvant setting and in combination with other cytotoxic agents.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>PMID: 9717821</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - adverse effects ; Antineoplastic Agents, Phytogenic - therapeutic use ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - radiotherapy ; Combined Modality Therapy ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Drug Administration Schedule ; Female ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - radiotherapy ; Male ; Medical sciences ; Middle Aged ; Paclitaxel - adverse effects ; Paclitaxel - therapeutic use ; Pharmacology. Drug treatments ; Prospective Studies ; Survival Analysis</subject><ispartof>Clinical cancer research, 1998-08, Vol.4 (8), p.1931-1936</ispartof><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2365934$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9717821$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CHOY, H</creatorcontrib><creatorcontrib>SAFRAN, H</creatorcontrib><creatorcontrib>AKERLEY, W</creatorcontrib><creatorcontrib>GRAZIANO, S. L</creatorcontrib><creatorcontrib>BOGART, J. A</creatorcontrib><creatorcontrib>COLE, B. F</creatorcontrib><title>Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>We conducted a prospective Phase II study to determine the response rate, toxicity, and 2-year survival rate of concurrent
weekly paclitaxel and radiation therapy (RT) for locally advanced unresectable non-small cell lung cancer. The weekly paclitaxel
regimen was designed to optimize the radiosensitizing properties of paclitaxel. Thirty-three patients with unresectable stage
IIIA and IIIB non-small cell lung cancer from six institutions were entered into the study between March 1994 and February
1995. Weekly i.v. paclitaxel (60 mg/m2; 3-h infusion) plus concurrent chest RT (60 Gy over 6 weeks) was delivered for 6 weeks.
Twenty-nine patients were evaluable for response. Three patients achieved a complete response (10%), and 22 patients (76%)
achieved a partial response, for an overall response rate of 86% (95% confidence interval, 68-96%). One patient progressed
during the therapy, and three patients had stable disease. Esophagitis was the principal toxicity. Grade 3 or 4 esophagitis
occurred in 11 patients (37%). One patient died of pneumonia after completion of therapy. Additional grade > or =3 toxicities
included pneumonitis (12%) and neutropenia (6%). One patient had a grade 3 hypersensitivity reaction. The median overall survival
duration for all 33 patients who entered the study was 20 months, and 1-, 2-, and 3-year overall survival rates were 60.6%,
33.3%, and 18.2%, respectively. The median progression-free survival duration for all 33 patients was 10.7 months, and 1-,
2-, and 3-year progression-free survival rates were 39.4%, 12.1%, and 6.1%, respectively. Weekly paclitaxel plus concurrent
RT is a well-tolerated outpatient regimen. The survival outcome from this regimen is encouraging and seems to be at least
equivalent to that of other chemotherapy/radiation trials. These findings warrant further clinical evaluation of weekly paclitaxel/RT
in Phase II trials in the neoadjuvant setting and in combination with other cytotoxic agents.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - adverse effects</subject><subject>Antineoplastic Agents, Phytogenic - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - radiotherapy</subject><subject>Combined Modality Therapy</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - radiotherapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Paclitaxel - adverse effects</subject><subject>Paclitaxel - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Survival Analysis</subject><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9j01LAzEQhhdRaq3-BCEHwdNCstmvHKX4USjoQc_LNJl0o2l2SbLW_nsjLV5mhnmfGd73LJuzqmpyXtTVeZpp0-a05MVldhXCJ6WsZLScZTPRsKYt2DyLbz0EJKsVid6AJYMme8QveyAjSGsi_KAl4BSRg5OT9-gi8aAMRDM4Env0MB6IHjyxgwSb7kB9g5OoiBtcHnZpRySmYie3JfJP8tfZhQYb8ObUF9nH0-P78iVfvz6vlg_rvC_qJuY1lBUFxcWmKhhjGmXFqAYpETVovVEpBdcNVVIogVTUNWV1iw0v2hZLgXyR3R7_jtNmh6obvdmBP3Sn9Em_O-kQknntkzsT_rGC15XgZcLuj1hvtv3eeOyOMTwGBC_7ruzajgnO-C8NRnPA</recordid><startdate>19980801</startdate><enddate>19980801</enddate><creator>CHOY, H</creator><creator>SAFRAN, H</creator><creator>AKERLEY, W</creator><creator>GRAZIANO, S. L</creator><creator>BOGART, J. A</creator><creator>COLE, B. F</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19980801</creationdate><title>Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer</title><author>CHOY, H ; SAFRAN, H ; AKERLEY, W ; GRAZIANO, S. L ; BOGART, J. A ; COLE, B. F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h267t-6a450ad39b52111fec510facceefaffbd9713f70dc9d9e09660168e73288e49e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - adverse effects</topic><topic>Antineoplastic Agents, Phytogenic - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - radiotherapy</topic><topic>Combined Modality Therapy</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - radiotherapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Paclitaxel - adverse effects</topic><topic>Paclitaxel - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CHOY, H</creatorcontrib><creatorcontrib>SAFRAN, H</creatorcontrib><creatorcontrib>AKERLEY, W</creatorcontrib><creatorcontrib>GRAZIANO, S. L</creatorcontrib><creatorcontrib>BOGART, J. A</creatorcontrib><creatorcontrib>COLE, B. F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CHOY, H</au><au>SAFRAN, H</au><au>AKERLEY, W</au><au>GRAZIANO, S. L</au><au>BOGART, J. A</au><au>COLE, B. F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>1998-08-01</date><risdate>1998</risdate><volume>4</volume><issue>8</issue><spage>1931</spage><epage>1936</epage><pages>1931-1936</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>We conducted a prospective Phase II study to determine the response rate, toxicity, and 2-year survival rate of concurrent
weekly paclitaxel and radiation therapy (RT) for locally advanced unresectable non-small cell lung cancer. The weekly paclitaxel
regimen was designed to optimize the radiosensitizing properties of paclitaxel. Thirty-three patients with unresectable stage
IIIA and IIIB non-small cell lung cancer from six institutions were entered into the study between March 1994 and February
1995. Weekly i.v. paclitaxel (60 mg/m2; 3-h infusion) plus concurrent chest RT (60 Gy over 6 weeks) was delivered for 6 weeks.
Twenty-nine patients were evaluable for response. Three patients achieved a complete response (10%), and 22 patients (76%)
achieved a partial response, for an overall response rate of 86% (95% confidence interval, 68-96%). One patient progressed
during the therapy, and three patients had stable disease. Esophagitis was the principal toxicity. Grade 3 or 4 esophagitis
occurred in 11 patients (37%). One patient died of pneumonia after completion of therapy. Additional grade > or =3 toxicities
included pneumonitis (12%) and neutropenia (6%). One patient had a grade 3 hypersensitivity reaction. The median overall survival
duration for all 33 patients who entered the study was 20 months, and 1-, 2-, and 3-year overall survival rates were 60.6%,
33.3%, and 18.2%, respectively. The median progression-free survival duration for all 33 patients was 10.7 months, and 1-,
2-, and 3-year progression-free survival rates were 39.4%, 12.1%, and 6.1%, respectively. Weekly paclitaxel plus concurrent
RT is a well-tolerated outpatient regimen. The survival outcome from this regimen is encouraging and seems to be at least
equivalent to that of other chemotherapy/radiation trials. These findings warrant further clinical evaluation of weekly paclitaxel/RT
in Phase II trials in the neoadjuvant setting and in combination with other cytotoxic agents.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>9717821</pmid><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 1998-08, Vol.4 (8), p.1931-1936 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_pubmed_primary_9717821 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; American Association for Cancer Research; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - radiotherapy Combined Modality Therapy Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Drug Administration Schedule Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - radiotherapy Male Medical sciences Middle Aged Paclitaxel - adverse effects Paclitaxel - therapeutic use Pharmacology. Drug treatments Prospective Studies Survival Analysis |
| title | Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T05%3A45%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20trial%20of%20weekly%20paclitaxel%20and%20concurrent%20radiation%20therapy%20for%20locally%20advanced%20non-small%20cell%20lung%20cancer&rft.jtitle=Clinical%20cancer%20research&rft.au=CHOY,%20H&rft.date=1998-08-01&rft.volume=4&rft.issue=8&rft.spage=1931&rft.epage=1936&rft.pages=1931-1936&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E9717821%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9717821&rfr_iscdi=true |